Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.02)
# 3,148
Out of 4,667 analysts
92
Total ratings
21.43%
Success rate
-11.77%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LUCD Lucid Diagnostics | Maintains: Overweight | $3 → $2 | $0.99 | +102.00% | 4 | Nov 15, 2024 | |
| ELUT Elutia | Reiterates: Overweight | $10 | $4.27 | +134.19% | 9 | Nov 15, 2024 | |
| NYXH Nyxoah | Reiterates: Overweight | $16 | $8.31 | +92.60% | 4 | Nov 5, 2024 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $14 | $13.88 | +0.86% | 2 | Oct 23, 2024 | |
| LMAT LeMaitre Vascular | Initiates: Neutral | $96 | $104.60 | -8.22% | 1 | Oct 15, 2024 | |
| NNOX Nano-X Imaging | Reiterates: Overweight | $14 | $5.89 | +137.69% | 8 | Sep 23, 2024 | |
| NPCE NeuroPace | Reiterates: Overweight | $18 | $8.90 | +102.25% | 4 | Aug 14, 2024 | |
| RCEL AVITA Medical | Reiterates: Overweight | $21 | $12.85 | +63.42% | 9 | Aug 9, 2024 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $3.5 | $1.77 | +97.31% | 5 | Aug 8, 2024 | |
| MDXG MiMedx Group | Reiterates: Overweight | $11 | $9.31 | +18.15% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.84 | +197.62% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $44 | $37.16 | +18.41% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $7 | $4.29 | +63.17% | 4 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.68 | +138.81% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.21 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.3 | $0.73 | +354.67% | 5 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $4.50 | +100.00% | 5 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.99 | +25.31% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 | $12.21 | +104.75% | 7 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $12 | $13.04 | -7.98% | 2 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $1.07 | +708.07% | 2 | Aug 18, 2023 |
Lucid Diagnostics
Nov 15, 2024
Maintains: Overweight
Price Target: $3 → $2
Current: $0.99
Upside: +102.00%
Elutia
Nov 15, 2024
Reiterates: Overweight
Price Target: $10
Current: $4.27
Upside: +134.19%
Nyxoah
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $8.31
Upside: +92.60%
CVRx, Inc.
Oct 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $13.88
Upside: +0.86%
LeMaitre Vascular
Oct 15, 2024
Initiates: Neutral
Price Target: $96
Current: $104.60
Upside: -8.22%
Nano-X Imaging
Sep 23, 2024
Reiterates: Overweight
Price Target: $14
Current: $5.89
Upside: +137.69%
NeuroPace
Aug 14, 2024
Reiterates: Overweight
Price Target: $18
Current: $8.90
Upside: +102.25%
AVITA Medical
Aug 9, 2024
Reiterates: Overweight
Price Target: $21
Current: $12.85
Upside: +63.42%
Pacific Biosciences of California
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.77
Upside: +97.31%
MiMedx Group
Aug 1, 2024
Reiterates: Overweight
Price Target: $11
Current: $9.31
Upside: +18.15%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.84
Upside: +197.62%
May 15, 2024
Reiterates: Overweight
Price Target: $44
Current: $37.16
Upside: +18.41%
May 14, 2024
Maintains: Overweight
Price Target: $5 → $7
Current: $4.29
Upside: +63.17%
May 3, 2024
Maintains: Overweight
Price Target: $3 → $4
Current: $1.68
Upside: +138.81%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.21
Upside: -
Apr 10, 2024
Reiterates: Neutral
Price Target: $3.3
Current: $0.73
Upside: +354.67%
Apr 4, 2024
Maintains: Overweight
Price Target: $10 → $9
Current: $4.50
Upside: +100.00%
Mar 1, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.99
Upside: +25.31%
Feb 27, 2024
Maintains: Overweight
Price Target: $25
Current: $12.21
Upside: +104.75%
Jan 19, 2024
Reiterates: Overweight
Price Target: $12
Current: $13.04
Upside: -7.98%
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $1.07
Upside: +708.07%